NCT03274765

Improved Medically Assisted Procreation Monitoring

Improved Medically Assisted Procreation (MAP) Monitoring

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Rennes University Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patient care in Medically Assisted Procreation (MAP) requires a close and regular monitoring of the evolution of the estradiol rate. This monitoring allows the dose and duration of treatment to be accurately adjusted for each woman (every 24 or 48 hours) up to 10 to 15 days of treatment with gonadotrophins. Oestradiol (E2) is secreted by the growing ovarian follicles and reflects their growth and maturity. Its plasma dosage makes it possible to monitor the ovarian response to stimulation. This monitoring involves several constraints amongst which disruption of work life, stress, fatigue that can alter the response to treatment

Detailed description

In order to improve the comfort of patients already under severe stress, simplification of this monitoring is proposed. The development of an immediate-release whole blood test for simplified monitoring of estradiol levels will provide considerable comfort in the management of patients. These patients are subjected to significant emotional and physical stress and the development of this test will reduce the negative consequences that result.

Conditions

• Infertility

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Dosage of oestradiol	The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech). This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation.

Timeline

• Start date: 2017-11-15
• Primary completion: 2018-06-15
• Completion: 2018-12-15
• First posted: 2017-09-07
• Last updated: 2017-09-07

Locations

1 site across 1 country: France